ライフサイエンスコーパス: pancytopenia

1 ive depletion of all hematopoietic lineages (pancytopenia).

2 e implicated in the development of anemia or pancytopenia.

3 resented to the Cancer Clinic with fever and pancytopenia.

4 ne patient with grade 4 acute GVHD developed pancytopenia.

5 , the patient developed new skin lesions and pancytopenia.

6 n with Babesia may be associated with marked pancytopenia.

7 -1995) that presented data on MTX-associated pancytopenia.

8 rtality due to graft-versus-host disease and pancytopenia.

9 multiple tick bites presented with fever and pancytopenia.

10 occlusive disease, capillary hemorrhage, and pancytopenia.

11 erized by hypocellular marrow and peripheral pancytopenia.

12 ed severe macrocytic normochromic anemia and pancytopenia.

13 cell (HSC) division, rapid HSC depletion and pancytopenia.

14 cell transplant and relapse with refractory pancytopenia.

15 up: one because of sepsis and one because of pancytopenia.

16 ell expansion and rescued animals from fatal pancytopenia.

17 irth, likely due to pulmonary hypoplasia and pancytopenia.

18 F-2alpha, encoded by the EPAS1 gene, exhibit pancytopenia.

19 veral stages that is characterized by severe pancytopenia.

20 hat the loss of EPAS1/HIF-2alpha resulted in pancytopenia.

21 One patient developed reversible pancytopenia.

22 ted with reduced doses because of persistent pancytopenia.

23 to produce immunosuppression had continuous pancytopenia.

24 tem cells prior to the development of severe pancytopenia.

25 e alterations of hematopoiesis, resulting in pancytopenia.

26 ic GVHD (60.7%; 95% CI, 50.3% to 71.1%), and pancytopenia (18.6%; 95% CI, 12.2% to 25.0%).

27 resented with fever, hepatosplenomegaly, and pancytopenia; 5 were previously healthy, but had a clini

28 Clinical features were skin rash (92%), pancytopenia (78%), and diarrhea (65%).

29 The patient suffered from pancytopenia, allergy, asthma, hearing impairment, and m

30 one marrow failure disorder characterized by pancytopenia and a hypocellular marrow.

31 two (2%) patients each in the benralizumab (pancytopenia and a suicide attempt, both considered unre

32 truction of hematopoietic stem cells causing pancytopenia and an empty bone marrow, which can be succ

33 nge of hematopoietic abnormalities including pancytopenia and BM hypoplasia similar to individuals wi

34 autosomal recessive disorder associated with pancytopenia and cancer susceptibility.

35 is a fatal genetic disorder associated with pancytopenia and cancer.

36 Deletion of Dot1l led to pancytopenia and failure of hematopoietic homeostasis, a

37 nd symptoms of GSD type Ib are hypoglycemia, pancytopenia and hepatosplenomegaly.

38 ressive decline in mentation associated with pancytopenia and hyperbilirubinemia.

39 mopoietic stem-cell disorder that results in pancytopenia and hypocellular bone marrow.

40 in addressing the immediate consequences of pancytopenia and in the long term because of the disease

41 mmon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection.

42 xpression interferes with the development of pancytopenia and marrow hypoplasia, validating a major r

43 marrow disorder characterized by peripheral pancytopenia and marrow hypoplasia.

44 Because of sustained pancytopenia and negligible gene marking, diagnostic bon

45 UCB, GVHD in 4 patients, and immune-mediated pancytopenia and nephrotic syndrome in the recipient of

46 She was diagnosed with pancytopenia and passed away after 5.5 months.

47 conferred in vivo resistance to BCNU-induced pancytopenia and significantly reduced BCNU-induced mort

48 tion of Lkb1 in adult mice results in severe pancytopenia and subsequent lethality.

49 estigated the mechanisms by which AML causes pancytopenia and suppresses patients' immune response.

50 ry disease in view of the longer duration of pancytopenia and susceptibility to life-threatening infe

51 Pancytopenia and systemic infections in particular were

52 tis, 1 patient with an idiopathic autoimmune pancytopenia, and 1 patient with immune thrombocytopenia

53 d with congenital abnormalities, progressive pancytopenia, and a predisposition to leukemia and solid

54 with the principal diagnosis of hemorrhage/ pancytopenia, and a secondary diagnosis of metastatic he

55 d of mice die due to complications of severe pancytopenia, and about two thirds progress to a fatal a

56 e characterized by congenital abnormalities, pancytopenia, and an increased incidence of cancer.

57 icant lymphadenopathy, fever, liver failure, pancytopenia, and erythrophagocytosis indicative of a he

58 oma presenting with fever of unknown origin, pancytopenia, and exposure to chicken manure.

59 locytic ehrlichiosis (HGE) results in fever, pancytopenia, and mild liver injury.

60 MDS, including multi-lineage myelodysplasia, pancytopenia, and occasional progression to overt leukem

61 mmatory diseases and characterized by fever, pancytopenia, and systemic inflammation.

62 [15%] of 62) and decreased neutrophil count, pancytopenia, and thrombocytopenia (two [3%] each).

63 icro Ci) produced no cures, induced profound pancytopenia, and was lethal to all mice.

64 Ataxia-pancytopenia (AP) syndrome is characterized by cerebella

65 iglyceridemia associated with rapamycin, and pancytopenia associated with MTX), and 4 were SSc-relate

66 Patients may present with lymphopenia or pancytopenia at diagnosis.

67 Bovine neonatal pancytopenia (BNP; previously known as idiopathic haemor

68 adult hematopoietic system results in severe pancytopenia but striking accumulation of HSCs and early

69 y immune-mediated bone marrow hypoplasia and pancytopenia, can be treated effectively with immunosupp

70 erations, the TIN2(+/DC) mice developed mild pancytopenia, consistent with hematopoietic dysfunction

71 panied with IBD-like disease with persistent pancytopenia despite moderate-dose G-CSF treatment.

72 We recently identified 3 patients in whom pancytopenia developed almost 50 years after high-level

73 rituximab, and 1 patient with an autoimmune pancytopenia developed PML after treatment with corticos

74 tient became febrile, and leukocytopenia and pancytopenia developed.

75 loblastic anemia, a disease characterized by pancytopenia due to the excessive apoptosis of hematopoi

76 munoconjugates are associated with transient pancytopenia during the first 3 months after treatment.

77 lastic syndrome (MDS) model characterized by pancytopenia, dysmegakaryopoiesis, dyserythropoiesis, an

78 -deficient mice develop fever, splenomegaly, pancytopenia, hypertriglyceridemia, hypofibrinogenemia,

79 We assessed two families with onset of pancytopenia in adults and detected two novel point muta

80 s may have implications in the management of pancytopenia in AIDS.

81 e, BM hypocellularity, ablation of HSCs, and pancytopenia in control mice, whereas irradiated, EPC-tr

82 irradiated Hoxa-9-/- mice develop persistent pancytopenia, indicating unusual sensitivity to ionizing

83 matopoietic recovery and protected mice from pancytopenia-induced death.

84 Pancytopenia is a major cause of morbidity in acute myel

85 egenerative bone marrow failure resulting in pancytopenia is another common problem in advanced stage

86 Pancytopenia is not an uncommon side effect of low-dose

87 opriate management of patients with moderate pancytopenia is unclear.

88 contrast to individuals with LIG4 mutations, pancytopenia leading to bone marrow failure has not been

89 d histological lesions of TA-GVHD, including pancytopenia, marked splenomegaly, wasting, engraftment

90 d by associated physical anomalies and early pancytopenia, may be present in otherwise phenotypically

91 G-CSF) in patients with glycogenosis-related pancytopenia might ameliorate the IBD-like disease throu

92 a hematopoietic stem cell leading to severe pancytopenia, multilineage differentiation impairment, a

93 3 and G4 events included anemia, leukopenia, pancytopenia, nausea, hyperbilirubinemia, hypophosphatem

94 ive microenvironment that contributes to the pancytopenia observed at diagnosis.

95 GVHD and pancytopenia occur commonly; GVHD is highly correlated w

96 ive trials, yielding an overall incidence of pancytopenia of 1.4% (7 of 511).

97 IST produced significant improvement in the pancytopenia of a substantial proportion of patients wit

98 how that cerebral folate levels, anemia, and pancytopenia of DHFR deficiency can be corrected by trea

99 he most common grade 3-4 adverse events were pancytopenia (one patient at level 2, one at level 3, an

100 Mortality in the disease results from pancytopenia or transformation to acute myeloid leukemia

101 icion of GvHD (skin rash, diarrhea, pyrexia, pancytopenia, or anemia, without an obvious alternative

102 ides within neutrophils and can cause fever, pancytopenia, or death.

103 rious types of sporadic tumors or idiopathic pancytopenia, peripheral-blood samples from 109 patients

104 A total of 70 patients with pancytopenia related to MTX therapy were identified (68

105 whereas others present with life-threatening pancytopenia representing a medical emergency.

106 od cell count is often incomplete, recurrent pancytopenia requires retreatment, and some patients dev

107 characterized by megaloblastic anemia and/or pancytopenia, severe cerebral folate deficiency, and cer

108 gous control animals receiving MMC exhibited pancytopenia shortly before death.

109 ociated with chromosomal breakage as well as pancytopenia, skin pigmentation, renal hypoplasia, cardi

110 auses a nonlethal phenotype characterized by pancytopenia, splenomegaly, and the accumulation of mono

111 nduce the severe marrow hypoplasia and fatal pancytopenia that is produced by injection of similar nu

112 Relapse was common, but severe pancytopenia usually did not recur.

113 minimal cumulative MTX dose leading to fatal pancytopenia was 10 mg, observed in one of our patients.

114 from reversion in a hematopoietic stem cell, pancytopenia was progressive.

115 Mitomycin C (MMC) dosing, known to induce pancytopenia, was used to challenge the transplanted ani

116 athy and splenomegaly; fever, hepatitis, and pancytopenia were common.

117 predisposing factors for the development of pancytopenia were described.

118 ned risk factors associated with MTX-related pancytopenia were identified.

119 l truncated AML1 mutant (S291fsX300) induced pancytopenia with erythroid dysplasia in transplanted mi

120 aplastic anemia, and ERCC6L2 patients, mild pancytopenia with myelodysplasia.

121 Affected animals developed fatal pancytopenia within 2 to 3 weeks, accompanied by BM olig

122 lly developed fever, skin rash, diarrhea, or pancytopenia within 2 to 6 weeks after their transplant.

123 Both monkeys recovered from pancytopenia within 4 weeks of whole body irradiation.